Cis-(1S)-N-methyl-7-(methoxycarbonyl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine | 291306-22-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: Cis-(1S)-N-methyl-7-(methoxycarbonyl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
• 英文别名: (5S,8S)-methyl 5-(3,4-dichlorophenyl)-8-(methylamino)-5,6,7,8-tetrahydronaphthalene-2-carboxylate；methyl (5S,8S)-5-(3,4-dichlorophenyl)-8-(methylamino)-5,6,7,8-tetrahydronaphthalene-2-carboxylate
• CAS: 291306-22-4
• 化学式: C₁₉H₁₉Cl₂NO₂
• 分子量: 364.271
• InChiKey: DACQOKGPDFDFGY-UGSOOPFHSA-N

物化性质

• 沸点：
  482.2±45.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Cis-(1S)-N-methyl-7-(methoxycarbonyl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine 在 二异丁基氢化铝 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以76%的产率得到Cis-(1S)-N-methyl-7-(hydroxymethyl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
  参考文献：
  名称：

  1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE COMPOUNDS USEFUL IN THERAPY

  摘要：

  公开号：

  EP1157002B1
• 作为产物：
  描述：

  cis-(1S)-N-methyl-7-carboxamido-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine 、 甲醇 在 硫酸 作用下， 生成 Cis-(1S)-N-methyl-7-(methoxycarbonyl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine
  参考文献：
  名称：

  COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES

  摘要：

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。

  公开号：

  US20100009970A1

文献信息

• Compositions and methods for treating medical conditions
  申请人：Lessem Jan N.

  公开号：US20080287406A1

  公开（公告）日：2008-11-20

  The invention features methods, compositions, and kits for the treatment of pain, pruritus, immunoinflammatory disorders, musculoskeletal disorders, and the reduction of serum C reactive protein (CRP) in a patient having a disease or conditions associated with an increased CRP level. The methods, compositions, and kits of the invention provide for a combination therapy including an SSRI and a corticosteroid.
• COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
  申请人：Sharma Geeta

  公开号：US20100081713A1

  公开（公告）日：2010-04-01

  The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).
• Compositions and methods for treatment of viral diseases
  申请人：Johansen Lisa M.

  公开号：US20100092479A1

  公开（公告）日：2010-04-15

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E).
• Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
  申请人：Montefeltro Andres Pablo

  公开号：US20120322991A1

  公开（公告）日：2012-12-20

  The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.
• COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES
  申请人：nLife Therapeutics, S.L.

  公开号：US20160235856A1

  公开（公告）日：2016-08-18

  The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a neurotransmitter transporter. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interests and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.